Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Vor Biopharma Q3 2026 Results: Net Loss of $86.7M, Loss Narrows

Vor Biopharma Inc. is a clinical-stage biotechnology company that remains pre-revenue, incurring significant net losses since inception. The company is focused on the development of its lead product candidate, telitacicept, and expects to require substantial additional funding to support ongoing research and clinical trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-86.7-812.7
EPS (diluted, $ a share)$-1.45$-121.63

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: VOR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Vor Biopharma Inc.: key numbers

Share price
$18.97Close, Nov 16
Market cap
$1.17B
Shares outstanding
61.43MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Vor Biopharma Inc.

All →
7:31 AM ET 8-K
Licensing Deal

Vor Biopharma Licensing Deal with RemeGen Co., Ltd. Worth $10M

Vor Biopharma expanded its existing partnership with RemeGen by entering into an amended and restated license agreement to add RC298, a next-generation dual BAFF/APRIL inhibitor, to its exclusive development and commercialization rights outside of Greater China. Vor Bio will pay an upfront cash payment of $10 million and issue a pre-funded warrant for 2.3 million shares, with RemeGen eligible for up to $630 million in development and regulatory milestones plus tiered royalties.

Value
$10M
Counterparty
RemeGen Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.